Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Carl Fletcher"'
Publikováno v:
Personality and Mental Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d066fc1689358e33d127b7641c9ed45f
https://doi.org/10.1002/pmh.1579
https://doi.org/10.1002/pmh.1579
Autor:
David Back, Marta Boffito, Sophie Collot-Teixeira, Laura Waters, Ferruccio De Lorenzo, Carl Fletcher, Anton Pozniak, Saliha Yilmaz, Brian Gazzard, John L. McGregor
Publikováno v:
Genomics. 96:57-65
Ritonavir is a protease inhibitor associated with metabolic abnormalities and cardiovascular disease. We have investigated the effects of low-dose ritonavir treatment on gene expression in peripheral blood mononuclear cells (PBMC) of 10 healthy donor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147cf0f2c4d625a6046d8c3c936e61e3
https://doi.org/10.1016/j.ygeno.2010.03.011
https://doi.org/10.1016/j.ygeno.2010.03.011
Autor:
Phillip Hay, Sherene S. Min, Yu Lou, Marta Boffito, Graeme Moyle, Ivy Song, Chris Higgs, Elena M. Guerini, Carl Fletcher, Geoffrey J. Yuen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 53:1532-1538
Abacavir (ABC) is administered either at 600 mg once daily (ABC 600 mg QD) or 300 mg twice daily (ABC 300 mg BID) in anti-human immunodeficiency virus (anti-HIV) combination therapy. Although ABC plasma pharmacokinetics following each regimen has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c86230d92ace9b4df43fee36121dafde
https://doi.org/10.1128/aac.01000-08
https://doi.org/10.1128/aac.01000-08
Autor:
Alan Winston, Izabela Tolowinska, David Back, Anton Pozniak, Lesley Robinson, Malte Schutz, Jennifer Unsworth, Brian Gazzard, Marta Boffito, Carl Fletcher
Publikováno v:
AIDS. 20:1401-1406
Introduction: Recent studies have described reduced absorption of certain protease inhibitors when administered with agents known to increase gastric pH. No clinically significant interactions between saquinavir absorption and gastric pH have previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b6a97bf0b93b91ce80da403abe0987
https://doi.org/10.1097/01.aids.0000233573.41597.8a
https://doi.org/10.1097/01.aids.0000233573.41597.8a
Autor:
Desmond Maitland, David Back, Anton Pozniak, Graeme Moyle, Andrew F. Hill, Brian Gazzard, Laura Dickinson, Marta Boffito, Mark T. Nelson, Carl Fletcher
Publikováno v:
Journal of Antimicrobial Chemotherapy. 55:542-545
The amount of ritonavir needed to enhance saquinavir hard gel (hg) plasma concentrations is unclear. Reduced ritonavir dosing may help to reduce ritonavir-related side effects and costs. This study examined the pharmacokinetics of twice-daily saquina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f379db6dc0ee954557781d5aa06eb5
https://doi.org/10.1093/jac/dki043
https://doi.org/10.1093/jac/dki043
Autor:
Graeme Moyle, Chris Higgs, Marta Boffito, Andrew F. Hill, Brian Gazzard, David Back, Mark T. Nelson, Carl Fletcher, Anton Pozniak, Laura Dickinson
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 37:1376-1384
Background In vitro synergy and complementary resistance profiles provide a strong rationale for combining fosamprenavir with saquinavir as part of a potent double-boosted protease inhibitor regimen. This study evaluated the steady-state pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9c0758a1cf7e45a6f4f15a84c50d083
https://doi.org/10.1097/01.qai.0000136060.65716.1a
https://doi.org/10.1097/01.qai.0000136060.65716.1a
Autor:
Graeme Moyle, Carl Fletcher, Laura Dickinson, Marta Boffito, David Back, Andrew F. Hill, Mark T. Nelson, Brian Gazzard, Anton Pozniak, Sundhiya Mandalia, Chris Higgs
Publikováno v:
Antiviral Therapy. 9:423-429
Objective To evaluate the steady-state pharmacokinetics and safety of two once-daily saquinavir/ritonavir (SQV/RTV) regimens, 1600/100 and 2000/100 mg, in HIV-positive patients. Methods Eighteen HIV-infected adults treated with the standard twice-dai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2db5d1ed5d03d1cf204c16d37708bcac
https://doi.org/10.1177/135965350400900315
https://doi.org/10.1177/135965350400900315
Autor:
Sarah E. Gibbons, Sundhiya Mandalia, Anton Pozniak, David Back, Darmishta Parmar, Mark T. Nelson, Nicola Smith, Brian Gazzard, Carl Fletcher, Alan Winston
Publikováno v:
AIDS. 18:572-574
Efavirenz induces the metabolism of co-administered drugs through the induction of CYP 3A4. It is often necessary to switch from efavirenz to nevirapine because of intolerance or toxicity. In a pharmacokinetic study we determined whether to dose-esca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1b6d51ded73a95e7d896af19ca335fa
https://doi.org/10.1097/00002030-200402200-00029
https://doi.org/10.1097/00002030-200402200-00029
Autor:
Marta Boffito, Diego Miralles, Alan Winston, Graeme Moyle, Anton Pozniak, Akil Jackson, Carl Fletcher, Brian Gazzard, Mark T. Nelson, Richard M. W. Hoetelmans, Izabela Tolowinska
Publikováno v:
AIDS (London, England). 21(11)
Cumulative antiretroviral exposure can result in multiclass HIV drug resistance. Experimental antiretroviral agents offer limited therapeutic benefit as resistance quickly develops after their introduction as a sole new agent.To assess the pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3348165cb026e8e45e4c4b7e9de1e59
https://pubmed.ncbi.nlm.nih.gov/17589191
https://pubmed.ncbi.nlm.nih.gov/17589191